Apalutamide, enzalutamide, and darolutamide all appear safe and well tolerated. Quality-of-life studies suggest no significant negative effects, and patients generally do well. All three agents cause fatigue and worsen hot flashes. In the SPARTAN trial, 25% of patients treated with apalutamide for nmCRPC experienced mild rash compared with 5% who received placebo.
Learn more about the safety profile of apalutamide, enzalutamide, and darolutamide.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Kyle A. Richards. Fast Five Quiz: Castration-Resistant Prostate Cancer - Medscape - Dec 02, 2020.